Trial Profile
Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Piclidenoson (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Can-Fite BioPharma
- 21 Apr 2022 Status changed from discontinued to completed.
- 23 Mar 2022 This trial has been completed in Bulgaria (End Date: 06 Jan 2022), according to 2 European Clinical Trials Database record.
- 26 Nov 2021 Status changed from recruiting to discontinued, according to a Can-Fite BioPharma media release.